Marco Meglio, Assistant Managing Editor for NeurologyLive, has been with the team since October 2019. Follow him on Twitter @marcomeglio1 or email him at mmeglio@neurologylive.com
Incidence of Poststroke Dementia Remains Highly Prevalent
November 23rd 2021The risk of dementia was substantial and front-loaded following stroke, with the 1-year prevalence similar to the estimate for dementia at any time point. The findings indicate a need for greater engagement between stroke and dementia care.
Prestroke Glycemic Control Associated With Subsequent Risk of Composite Vascular Events
November 22nd 2021The optimal range of HbA1c between 6.8% and 7.0% at admission was estimated to have the minimum risk for composite vascular events and stroke recurrence, with notably different levels according to stroke subtype.
Neflamapimod Displays Robust Efficacy in Pure Lewy Body Dementia Pathology
November 19th 2021The magnitude of neflamapimod’s effect on several efficacy measures proved to be consistent with the mechanism of action and prior preclinical data, with p-tau181 data suggesting a stronger effect on nonmixed Lewy body pathology.
Plasma GFAP Levels Significant in Detecting Amyloid Pathology Across Alzheimer Continuum
November 18th 2021The findings, which suggest that high plasma GFAP levels are parallel with AD and are markers of tau pathology, hold important implications in facilitating the detection of Alzheimer disease, particularly in the preclinical stage.
Urgent Secondary Prevention of TIA or Minor Stroke Has Long-Term Positive Effect
November 16th 2021The long-term benefits observed were due to maintenance of the early effect, rather than any additional benefit accrued after 90 days of the initial event, with no evidence either of rebound or loss of benefit.
Autologous Adipose Stem Cells Are Safe in Alzheimer Disease, Slightly Improve Cognitive Function
November 12th 2021Despite the cohort only consisting of 3 patients with Alzheimer disease, autologous cellular therapy data highlighted the potential of the treatment’s results on cognitive assessments such as Montreal Cognitive Assessment.
Subcutaneous ABBV-951 Infusion Superior in Parkinson Disease to Oral Formulation
November 11th 2021Those who received an infusion of ABBV-951, consisting of foslevodopa/foscarbidopa, showed statistically significant increases in hours of ON time without troublesome dyskinesia compared with oral levodopa/carbidopa.
Preoperative RBD Not Linked to Altered Outcomes in Post DBS Parkinson Disease
November 11th 2021Twelve months after subthalamic deep brain stimulation, patients with and without RBD had MDS-UPDRS IV score decrease, MDS-UPDRS III MedOff decrease, and total LEDD decrease, with no between group difference.
NeuroVoices: Alexander Merkler, MD, MS, on Anticoagulants for Stroke and Ventricular Dysfunction
November 10th 2021The assistant professor of neurology at Weill Cornell Medicine provided thoughts on his exploratory analysis, which found rivaroxaban to be superior to aspirin in reducing recurrent stroke.